基线低密度脂蛋白胆固醇水平与依折麦布联合他汀治疗在IMPROVE-IT研究中的临床结局
IMPROVE-IT随机双盲安慰剂对照试验纳入17,999例急性冠脉综合征后患者,按基线LDL-C分为50-<70、70-<100和100-125 mg/dL三组,比较依折麦布/辛伐他汀与安慰剂/辛伐他汀。结果显示,无论基线LDL-C水平如何,依折麦布联合他汀对主要终点的疗效一致,支持即使基线LDL-C<70 mg/dL也使用依折麦布强化降脂。
要点
- 急性冠脉综合征后患者无论基线LDL-C水平,依折麦布联合他汀均一致降低心血管事件风险。
- 基线LDL-C 50-<70 mg/dL患者中,依折麦布/辛伐他汀主要终点HR为0.92(95%CI 0.80-1.05)。
- 安全性终点无基线LDL-C相关显著治疗交互作用。
核心结论
- 在急性冠脉综合征后患者中,依折麦布联合他汀可一致降低心血管事件风险,不受基线LDL-C水平影响。
- 支持即使基线LDL-C<70 mg/dL的患者也使用依折麦布进行强化降脂治疗。
研究设计与样本
- IMPROVE-IT为双盲、安慰剂对照、随机试验,比较依折麦布/辛伐他汀与安慰剂/辛伐他汀。
- 共纳入17,999例急性冠脉综合征后患者,中位随访6年。
- 按基线LDL-C分为50-<70、70-<100和100-125 mg/dL三组。
主要发现
- 主要终点为心血管死亡、主要冠脉事件或卒中的复合终点。
- 4个月时治疗组间中位LDL-C绝对差异相似(17-20 mg/dL)。
- 依折麦布/辛伐他汀对主要终点的效应在各基线LDL-C组一致:50-<70 mg/dL组HR 0.92(95%CI 0.80-1.05),70-<100 mg/dL组HR 0.93(95%CI 0.87-1.01),100-125 mg/dL组HR 0.94(95%CI 0.86-1.03),P交互=0.95。
- 4个月时治疗组间每1 mmol/L LDL-C差异的归一化相对风险降低:基线50-<70组21%,70-<100组16%,100-125组13%(P交互=0.91)。
- 安全性终点无基线LDL-C相关显著治疗交互作用。
关键数值与推荐
- 2018年美国胆固醇管理指南推荐:对于最大耐受他汀治疗后LDL-C≥70 mg/dL的极高危二级预防患者,加用依折麦布。
临床怎么用
- 急性冠脉综合征后患者可考虑依折麦布联合他汀强化降脂,即使基线LDL-C<70 mg/dL。
- 治疗决策应基于整体风险评估,而非仅依据基线LDL-C水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2018 U.S. cholesterol management guideline recommends additional lipid-lowering therapy with ezetimibe for secondary prevention in very high-risk patients with low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL despite maximally tolerated statin. OBJECTIVES: The purpose of this study was to evaluate the relationship between baseline LDL-C above and below 70 mg/dL and the benefit of adding ezetimibe to statin in patients post-acute coronary syndrome (ACS). METHODS: IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) was a double-blind, placebo-controlled, randomized trial of ezetimibe/simvastatin vs placebo/simvastatin in post-ACS patients followed for 6 years (median). A total of 17,999 patients were stratified by LDL-C at qualifying event into 3 groups (50-<70, 70-<100, and 100-125 mg/dL). The primary endpoint was a composite of cardiovascular death, major coronary events, or stroke. RESULTS: Absolute differences in median LDL-C achieved at 4 months between treatment arms were similar (17-20 mg/dL). The effect of ezetimibe/simvastatin vs placebo/simvastatin on primary endpoint was consistent regardless of baseline LDL-C of 50-<70 mg/dL (HR: 0.92 [95% CI: 0.80-1.05]), 70-<100 mg/dL (HR: 0.93 [95% CI: 0.87-1.01]), or 100-125 mg/dL (HR: 0.94 [95% CI: 0.86-1.03]; P interaction = 0.95). Normalized relative risk reductions per 1-mmol/L difference in achieved LDL-C at 4 months between treatment arms were 21% in patients with baseline LDL-C of 50-<70 mg/dL, 16% in those with 70-<100 mg/dL, and 13% in those with 100-125 mg/dL (P interaction = 0.91). No significant treatment interactions by baseline LDL-C were present for safety endpoints. CONCLUSIONS: Adding ezetimibe to statin consistently reduced the risk for cardiovascular events in post-ACS patients irrespective of baseline LDL-C values, supporting the use of intensive lipid-lowering therapy with ezetimibe even in patients with baseline LDL-C <70 mg/dL. (IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin [Ezetimibe/Simvastatin] vs Simvastatin [P04103]; NCT00202878).
引用
- Oyama K, Giugliano RP, Blazing MA, et al. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. J Am Coll Cardiol. 2021. PMID: 34620406. doi:10.1016/j.jacc.2021.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。